Efficacy and safety of risperidone for attention deficit hyperactivity disorder and disruptive behaviour disorders: a systematic review and meta-analysis

CONCLUSION: Risperidone augmentation reduces aggression and oppositional symptoms in children and adolescents with ADHD and comorbid DBDs. Nonetheless, risperidone is associated with risks of weight gain, elevated serum prolactin, and metabolic syndrome.

via https://pubmed.ncbi.nlm.nih.gov/41916941/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20260412010908&v=2.19.0.post6+133c1fe